Although allogeneic stem cell transplantation (SCT) is a curative treatment for hematological malignancies, chronic graft-versushost disease (cGVHD), one of the major complications after SCT, impairs the recipient's quality of life. Therefore, the strategy against cGVHD should be improved.
Recently, it has been reported that the fibrotic change in cGVHD is associated with the activation of transforminggrowth-factor-b (TGFb) and platelet-derived-growth-factor receptor (PDGFR) pathways. 1, 2 On the other hand, imatinib, a potent tyrosine kinase inhibitor, is known to inhibit the activation of those pathways, 3 and has been investigated for the treatment for steroid-refractory skin cGVHD. 4, 5 Although these studies showed that imatinib was effective as salvage treatment for refractory cGVHD, it remains unknown whether the prophylactic imatinib after SCT affects the incidence and severity of cGVHD.
Therefore, we reviewed the clinical records of patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (PhALL) who underwent allogeneic SCT between 1999 and 2009 and survived without relapse for more than 100 days after SCT at eight institutions participating in the Kanto Study Group for Cell Therapy. In all, 76 patients who did not receive imatinib after SCT until hematological relapse or last follow-up were included in the non-imatinib group. Besides, 20 patients who received imatinib for the prevention of leukemia relapse for at least 3 months after transplantation and who experienced no cGVHD before imatinib administration were included in the imatinib group . Patients who received imatinib for less than 3 months were not included. The diagnosis of cGVHD was based on characteristic manifestations and/or pathological findings. 6 The severity of cGVHD was classified according to the traditional Seattle criteria. 7 In addition, the severity score according to the National Institute of Health Consensus recommendations was also used for the comparison of the severity in each target organ between the two groups, including skin, eye and oral (sicca syndrome), liver, lung, gut, and others, although there was a difficulty in retrospective grading. 6 This analysis was approved by the institutional review board of Jichi Medical University.
The imatinib group included 2 and 18 patients with CML and PhALL, respectively. The non-imatinib group included 43 and 33 patients with CML and PhALL, respectively. Besides, 1 and 33 CML patients were in chronic phase and 17 and 30 PhALL patients were in 1st complete remission in the imatinib and non-imatinib groups, respectively. The proportion of patients with PhALL was significantly higher in the imatinib group (P ¼ 0.0003). Although more patients in the imatinib group underwent SCT from an alternative donor (14 and 43 patients in the imatinib and non-imatinib group, respectively, P ¼ 0.017) and received tacrolimus-based GVHD prophylaxis (14 and 30 patients in the imatinib and non-imatinib group, respectively, P ¼ 0.0099), there was no difference in the incidence of grade 2-4 acute GVHD (Table 1) . None received anti-thymocyte globulin-containing conditioning nor T cell depleted graft.
All 20 patients in the imatinib group received imatinib after SCT, but nilotinib or dasatinib was substituted for imatinib in 2 patients at 5 and 12 months after SCT, respectively. The median starting doses of imatinib, nilotinib, and dasatinib were 400 mg (range 100-600), 800 mg, and 70 mg, respectively. The median duration between SCT and the start of imatinib was Abbreviations: BU, busulfan; CB, cord blood; CML, chronic myeloid leukemia; CsA, cyclosporine; CY, cyclophosphamide; Donor sexrecipient sex; FK, tacrolimus; GVHD, graft-versus-host disease; MMUD, mismatched unrelated donor; MMRD, mismatched related donor; MRD, matched related donor; MUD, matched unrelated donor; PhALL, Philadelphia positive acute lymphoblastic leukemia; RIC, reduced-intensity conditioning; SCT, stem cell transplantation. *P-value o0.05 was considered significant.
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65 days (range 13-219 days). Imatinib was started within 100 days after SCT in 16 of the 20 patients (in 18 patients within 120 days after SCT). The median duration of imatinib administration was 170 days (range 115-1284 days). The reasons for the administration of imatinib included planned administration in 14, molecular relapse or minimal residual disease in 5 patients, and isolated central nervous system relapse after SCT in 1 patient. In total, 62 patients experienced cGVHD. The 3-year cumulative incidence of cGVHD and extensive cGVHD was 41.1 and 22.0%, respectively, in the imatinib group, and 71.3 and 53.0%, respectively, in the non-imatinib groups (P ¼ 0.0083 and P ¼ 0.0072) (Figure 1a and b) . The details of clinical features of cGVHD symptoms are shown in Table 2 . Sicca syndrome (P ¼ 0.047) and gut involvement (P ¼ 0.036) were observed less frequently in the imatinib group. The incidences of skin and lung cGVHD were also lower in the imatinib group, but these differences were not statistically significant. No lung involvement was observed during imatinib administration. The severity score of cGVHD was also significantly lower in the imatinib group in sicca syndrome (P ¼ 0.038) and gut involvement (P ¼ 0.038). The severity in skin involvement was also lower during imatinib administration in the imatinib group. Finally, the overall severity of cGVHD through the clinical course was significantly lower in the imatinib group (P ¼ 0.029).
Multivariate analysis revealed that cord-blood transplantation (relative risk (RR) ¼ 0.129, P ¼ 0.045) and the administration of post-SCT imatinib as a time-dependent covariate (RR ¼ 0.266, P ¼ 0.013) were the significant independent predictive factors for a lower incidence of cGVHD. Younger age (RR ¼ 1.035, P ¼ 0.011) and post-SCT imatinib administration (RR ¼ 0.252, P ¼ 0.0087) were significant for lower incidence of extensive cGVHD (Table 3) . GVHD prophylaxis and imatinib administration before SCT did not affect the incidence of cGVHD. The very small number of CML cases in the imatinib group might have resulted in the finding that the diagnosis of CML, which previously was reported as a risk factor for cGVHD, did not remain significant in multivariate analysis.
TGFb and PDGF are thought to have a role in the pathogenesis of fibrosis. Imatinib inhibits intracellular signaling of these fibrotic cytokines. 3 Although imatinib was recently reported to be a promising salvage treatment for refractory cGVHD, 4, 5 this study showed for the first time that imatinib may also be effective as prophylaxis for cGVHD. This might be the reason why no cGVHD was observed in a post-SCT imatinib trial for prevention of disease progression. Abbreviations: GVHD, graft-versus-host disease; SCT, stem cell transplantation. *P-value o0.05 was considered significant.
Based on reports of imatinib as an inhibitor of TGFb and PDGFR, 3 we had initially predicted that imatinib might strongly affect skin and lung involvement. In fact, the incidences of skin and lung cGVHD were reduced in the imatinib group, although the difference was not statistically significant. In addition, when we focused on the severity only during imatinib administration, the severity in skin involvement was lower and no lung involvement was observed in the imatinib group. Furthermore, a deterioration of sclerotic cGVHD was observed after the discontinuation of imatinib in four patients. These findings suggest that sclerotic involvement might be inhibited mainly during imatinib administration through the inhibition of TGFb or PDGF. In this study, however, prophylactic imatinib administration appeared mainly to reduce the incidence and severity of sicca and gut involvement. Although the actual mechanism is unclear, suppression of mast-cell activation in intestinal mucosa and salivary glands by inhibition of the c-kit pathway by imatinib might have been involved as well, similar to Sjogren's disease and inflammatory bowel diseases. 9, 10 In addition, imatinib inhibits T-cell proliferation in vitro.
11 Therefore, imatinib might prevent cGVHD through a direct immunosuppressive effect.
In summary, the incidence and severity of cGVHD were reduced by imatinib administration after SCT. However, this study has limitations because of its retrospective nature. A large prospective study is warranted to assess the prophylactic impact of imatinib on the incidences of leukemia relapse and cGVHD after allogeneic SCT for PhALL and CML.
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The authors declare no conflict of interest. Acute myeloid leukemia (AML) is a heterogeneous disease. Among chromosomal numerical aberrations, trisomy 8 ( þ 8) is the most common chromosomal change, conferring an intermediate prognosis, and is associated with the t(7;12), t(9;11) and t(1;11) translocations. 1 Alone, trisomy 8 does not appear to be sufficient for leukemogenesis but may be associated with an increased risk of myeloid malignancy. 1 To investigate further the contribution of þ 8 to AML, we determined the gene expression signature associated specifically with this numerical chromosomal abnormality using large, previously reported, AML microarray data sets 2, 3 and data sets derived from AML cell lines. We have identified a novel association between HOXA gene upregulation and þ 8 AML providing new insight into the potential contribution of þ 8 to AML pathogenesis.
We first analyzed the large AML microarray data set (Affymetrix HGU133A, Santa Clara, CA, USA) from the study by Valk et al.
2 (GSE1159). Criteria for inclusion were patients with a þ 8 karyotype without any other karyotypic abnormalities, such as translocations, or other numerical chromosomal aberrations. Patients with a þ 8 karyotype and mutations in FLT3, EVI1, RAS, CEBPA or NPM1 genes were not excluded. Data were normalized with Robust Multichip Average (RMA) and the gene expression change for each gene determined in the þ 8 AML group (n ¼ 16), relative to the expression level in normal bone marrow mononuclear cells (NBM, n ¼ 5). This approach focused on genes in the selected AML group that may contribute to the leukemic phenotype by virtue of their association with the block in differentiation, increased selfrenewal, increased survival and proliferative potential. To generate the final þ 8 AML gene set, we selected genes that are selectively differentially expressed in þ 8 AML compared to NBM but not differentially expressed in the other common AML numerical chromosome abnormalities, monosomy 7 (À7) and À7q. Analysis was performed using linear modeling analysis package available from the Bioconductor (http://www. bioconductor.org/). Genes with multiple probes were filtered based on an adjusted false discovery rate P-value controlled using Benjamini-Hochberg method. The analysis was performed using R (http://www.r-project.org/). This approach identified 90 genes (false discovery rate P-value o0.01) that display selective differential gene expression in AML associated with trisomy 8 (Figure 1 ). The top 10 up-and downregulated genes ranked based on fold change are shown in Table 1 .
Seven of the differentially regulated genes were located on chromosome 8 (marked with a double asterisk in Figure 1 ) and, as may be predicted from the þ 8 genotype and shown by previous gene expression studies (reviewed by Paulsson and Johansson 1 ), the expression of six of these was upregulated. Unsupervised clustering with MeV (http://www.tm4.org/mev/) using the þ 8 AML gene signature showed that þ 8 AML clustered together with the mixed-lineage leukemia (MLL) translocation group and with normal karyotype AML (Figure 1 ) This is in line with the clinical findings that þ 8, MLL and normal karyotype AML form a well-defined prognostic group (G1) with intermediate outcome 4 ( Figure 1) . Of significant interest, we identified several HOX genes (HOXA9, HOXA10 and HOXA1) that display increased expression in the þ 8 AML group relative to most other karyotypic groups and NBM (Figure 2 ). Several HOX genes from the HOXA cluster, in particular HOXA9, have important roles in hematopoiesis and leukemogenesis. 5 This is the first report of increased HOX gene expression as a feature of þ 8 AML, although increased HOX gene expression has been reported in AML with MLL rearrange-
